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Articles
Effects of tranexamic acid on death, disability, vascular 
occlusive events and other morbidities in patients with 
acute traumatic brain injury (CRASH-3): a randomised, 
placebo-controlled trial
The CRASH-3 trial collaborators*
Summary
Background Tranexamic acid reduces surgical bleeding and decreases mortality in patients with traumatic extracranial 
bleeding. Intracranial bleeding is common after traumatic brain injury (TBI) and can cause brain herniation and 
death. We aimed to assess the effects of tranexamic acid in patients with TBI.
Methods This randomised, placebo-controlled trial was done in 175 hospitals in 29 countries. Adults with TBI who 
were within 3 h of injury, had a Glasgow Coma Scale (GCS) score of 12 or lower or any intracranial bleeding on 
CT scan, and no major extracranial bleeding were eligible. The time window for eligibility was originally 8 h but in 
2016 the protocol was changed to limit recruitment to patients within 3 h of injury. This change was made blind to the 
trial data, in response to external evidence suggesting that delayed treatment is unlikely to be effective. We randomly 
assigned (1:1) patients to receive tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or 
matching placebo. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs 
that were identical apart from the pack number. Patients, caregivers, and those assessing outcomes were masked to 
allocation. The primary outcome was head injury-related death in hospital within 28 days of injury in patients treated 
within 3 h of injury. We prespecified a sensitivity analysis that excluded patients with a GCS score of 3 and those with 
bilateral unreactive pupils at baseline. All analyses were done by intention to treat. This trial was registered with 
ISRCTN (ISRCTN15088122), ClinicalTrials.gov (NCT01402882), EudraCT (2011-003669-14), and the Pan African 
Clinical Trial Registry (PACTR20121000441277).
Results Between July 20, 2012, and Jan 31, 2019, we randomly allocated 12 737 patients with TBI to receive tranexamic 
acid (6406 [50·3%] or placebo [6331 [49·7%], of whom 9202 (72·2%) patients were treated within 3 h of injury. 
Among patients treated within 3 h of injury, the risk of head injury-related death was 18·5% in the tranexamic acid 
group versus 19·8% in the placebo group (855 vs 892 events; risk ratio [RR] 0·94 [95% CI 0·86–1·02]). In the 
prespecified sensitivity analysis that excluded patients with a GCS score of 3 or bilateral unreactive pupils at 
baseline, the risk of head injury-related death was 12·5% in the tranexamic acid group versus 14·0% in the placebo 
group (485 vs 525 events; RR 0·89 [95% CI 0·80–1·00]). The risk of head injury-related death reduced with 
tranexamic acid in patients with mild-to-moderate head injury (RR 0·78 [95% CI 0·64–0·95]) but not in patients 
with severe head injury (0·99 [95% CI 0·91–1·07]; p value for heterogeneity 0·030). Early treatment was more 
effective than was later treatment in patients with mild and moderate head injury (p=0·005) but time to treatment 
had no obvious effect in patients with severe head injury (p=0·73). The risk of vascular occlusive events was similar 
in the tranexamic acid and placebo groups (RR 0·98 (0·74–1·28). The risk of seizures was also similar between 
groups (1·09 [95% CI 0·90–1·33]).
Interpretation Our results show that tranexamic acid is safe in patients with TBI and that treatment within 3 h of 
injury reduces head injury-related death. Patients should be treated as soon as possible after injury.
Funding National Institute for Health Research Health Technology Assessment, JP Moulton Charitable Trust, 
Department of Health and Social Care, Department for International Development, Global Challenges Research 
Fund, Medical Research Council, and Wellcome Trust (Joint Global Health Trials scheme).
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Each year, worldwide, there are more than 60 million 
new cases of traumatic brain injury (TBI).1 Road traffic 
crashes and falls are the main causes and the inci­
dence is increasing.1 Intracranial bleeding is a common 
complication of TBI and increases the risk of death and 
disability.2 Although bleeding can start from the moment 
of impact, it often continues for several hours after 
injury.3,4 Ongoing intracranial bleeding can lead to 
raised intracranial pressure, brain herniation, and death. 
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Tranexamic acid reduces bleeding by inhibiting the 
enzymatic breakdown of fibrin blood clots (fibrinolysis). 
The CRASH­2 trial5,6 showed that in patients with 
trauma with major extracranial bleeding, early admin­
istration (within 3 h of injury) of tranexamic acid 
reduces bleeding deaths by a third. Subsequent anal­
yses showed that even a short delay in treatment 
reduces the benefit of tranexamic acid administration.7 
On the basis of these results, tranexamic acid was 
included in guide lines for the pre­hospital care of 
patients with trauma, although patients with isolated 
TBI were specifically excluded. However, increased 
fibrinolysis, as indicated by increased concentrations 
of fibrinogen degradation products, is often seen in 
patients with TBI and predicts intracranial haemor­
rhage expansion.8 Therefore, early administration of 
tranexamic acid in patients with TBI might prevent or 
reduce intracranial haemorrhage expansion and thus 
avert brain herniation and death.
Before the CRASH­3 trial, only two small trials of 
tranexamic acid in patients with TBI had been done.9,10 
Meta­analysis of these trials showed a reduction in 
mor tality with tranexamic acid (risk ratio [RR] 0·63 
[95% CI 0·40–0·99]) but provided no evidence about the 
effect of tranexamic acid on disability or adverse events. 
The CRASH­3 trial aimed to quantify the effects of 
tranexamic acid on head injury­related death, disability, 
and adverse events in patients with TBI.11
Methods
Study design and participants
The CRASH­3 trial was an international, multi­centre, 
randomised, placebo­controlled trial of the effects of 
tranexamic acid on death and disability in patients with 
TBI. Adults with TBI who were within 3 h of injury, had 
a Glasgow Coma Scale (GCS) score of 12 or lower or 
any intracranial bleeding on CT scan, and no major 
extracranial bleeding were eligible. The fundamental 
eligibility criterion was that the responsible clinician 
was substantially uncertain as to the appropriateness 
of tranexamic acid treatment. The time window for 
eligibility was originally within 8 h of injury. However, on 
Sept 6, 2016, in response to evidence external to the trial 
indicating that tranexamic acid is unlikely to be effective 
when initiated beyond 3 h of injury,6,12,13 the trial steering 
committee amended the protocol to limit recruitment to 
within 3 h of injury and the primary endpoint was 
changed to head injury death in hospital within 28 days 
of injury for patients treated within 3 h of injury. This 
change was made without reference to the unblinded 
trial data. The data monitoring committee was not 
consulted about the change. The trial was done according 
to good clinical practice guidelines.
Because of the nature of their injury, most patients with 
TBI are unable to provide informed consent to participate 
in a clinical trial. As acknowledged in the Declaration of 
Helsinki, patients who are incapable of giving consent are 
Research in context
Evidence before this study
Evidence from the CRASH-2 trial that administration of 
tranexamic acid within 3 h of injury reduces death in patients 
with traumatic extracranial bleeding raised the possibility that 
tranexamic acid might reduce death from traumatic intracranial 
bleeding. Intracranial bleeding is common after traumatic brain 
injury (TBI) and increases head injury-related death and 
disability. Before the CRASH-3 trial, we made a systematic 
search for all randomised trials of tranexamic acid in acute 
traumatic injury. We searched PubMed, Science Citation Index, 
National Research Register, Zetoc, SIGLE, Global Health, 
LILACS, Current Controlled Trials, the Cochrane Injuries Group 
Specialised Register, CENTRAL, MEDLINE, and Embase for all 
publications until July 15, 2010. Details of our search were 
published previously. We found two small randomised trials of 
tranexamic acid in traumatic brain injury with a total of 
510 patients. Meta-analysis of the two trials showed a 
statistically significant reduction in death with tranexamic acid. 
However, given the small size of the trials, we considered this 
evidence to be hypothesis generating, requiring confirmation 
in larger randomised trials.
Added value of this study
Our study found that the risk of death from head injury was 
reduced in patients treated with tranexamic acid, particularly 
when patients who had a Glasgow Coma Scale score of 3 and 
those with bilateral unreactive pupils at baseline were 
excluded. We found no evidence of any increase in disability 
among survivors. The risk of vascular occlusive events was 
similar in the tranexamic acid and placebo groups.
Implications of all the available evidence
On Aug 30, 2019, an updated search for randomised trials of 
the early administration of tranexamic acid in patients with 
traumatic brain injury identified one randomised trial in 
addition to the CRASH-3 trial. This study was a randomised 
trial of pre-hospital tranexamic acid in 967 patients with 
traumatic brain injury. The dose of tranexamic acid was the 
same as in the CRASH-3 trial and patients with a GCS score of 
3 and those with unreactive pupils at baseline were also 
excluded. When the two trials were pooled, we found a 
reduction in head injury-related death with tranexamic acid 
and no evidence of an increased risk in vascular occlusive 
events or seizures. Combining the results of all available 
randomised trials shows a reduction in head injury-related 
death in patients treated with tranexamic acid. Early 
administration of tranexamic acid should be considered in 
patients with traumatic brain injury.
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an exception to the general rule of informed consent in 
clinical trials.14 In this trial, consent was usually sought 
from the patient’s relative or a legal representative. If no 
such representative was available, the study proceeded 
with the agreement of two clinicians. If the patient 
regained capacity, he or she was told about the trial and 
written consent was sought to continue participation. If 
the patient or their representative declined consent, 
participation stopped. If patients were included in the 
trial but did not regain capacity, consent was sought 
from a relative or legal representative. We adhered to the 
requirements of the local and national ethics committees.
Randomisation and masking
An independent statistician from Sealed Envelope 
(London, UK) prepared the randomisation codes and 
gave them to the drug packers so that treatment packs 
could be prepared. We randomly allocated eligible 
patients to receive tranexamic acid or matching placebo 
(0·9% sodium chloride) by intravenous infusion. After 
baseline information was collected on the entry form, the 
lowest numbered treatment pack remaining was taken 
from a box of eight treatment packs. At this point, 
provided that the ampoules inside the treatment pack 
were intact, the patient was considered to be randomised. 
Entry form data were entered into a secure online 
database by the trial investigators. Participants and study 
staff (site investigators and trial coordinating centre staff) 
were masked to allocation. An emergency unblinding 
service was available for use if the clinician believed 
that clinical manage ment depended importantly on 
knowledge of whether the patient received tranexamic 
acid or placebo. The tranexamic acid was manufactured 
by Pfizer (Sandwich, UK). The Torbay and South Devon 
Healthcare NHS Trust (UK) prepared the 0·9% sodium 
chloride placebo. Ampoules and packaging were identical 
in appearance. The preparation of the treatment packs 
was done by Bilcare (Crickhowell, UK), by removal of 
the manu facturer’s label and replacement with the trial 
label and treatment pack number. Pack label texts were 
identical for tranexamic acid and placebo. We checked 
the coding of the blinded ampoules by randomly testing 
each batch of treatments and doing high performance 
liquid chromatography to identify the contents.
Procedures
Patients were randomly allocated to receive a loading 
dose of 1 g of tranexamic acid infused over 10 min, 
started immediately after randomisation, followed by 
an intravenous infusion of 1 g over 8 h, or matching 
placebo. Every patient was assigned a uniquely numbered 
treatment pack, which contained four ampoules of either 
tranexamic acid (500 mg) or placebo, one 100 mL bag of 
0·9% sodium chloride (to use with the loading dose), a 
syringe and needle, stickers with the trial details and 
randomisation number (for attaching to infusion bags, 
forms, and the medical records), and instructions. 
We separately provided information for patients and 
representatives, consent forms, and data collection 
forms. The stickers, instructions, leaflets, and forms 
were in local languages. Once randomised, we collected 
outcome data even if the treatment was not given. 
Outcome data were collected 28 days after randomisation, 
at discharge from the randomising hospital, or at death 
(whichever was first). Because the trial was assessed as 
low risk (tranexamic acid is widely used and the trial was 
considered to have a low risk of bias), we used central 
trial monitoring and central statistical monitoring in 
conjunction with investigator training, meetings, and 
written guidance. Trial investigators and their institutions 
provided direct access to the source data for trial­related 
monitoring, audits, and regulatory inspections. We 
planned to monitor approximately 10% of patient records 
on site. However, after changing the primary outcome 
we expanded our monitoring plan to include patients 
enrolled within 3 h of injury who subsequently died. 
We monitored 2436 (19%) of 12 737 patient records onsite 
or remotely (using videocall or telephone), including 
1161 (67%) of the patients who died from head injury 
(the primary outcome). The team of monitors worked 
alongside local trial teams to verify data from the source 
data, including pre­hospital ambulance cards, admission 
registers, emergency department notes, CT scans, sur­
gery notes, death registers, and death certificates.
Outcomes
The primary outcome was head injury­related death in 
hospital within 28 days of injury in patients randomly 
assigned within 3 h of injury. Because most patients with 
TBI with a GCS score of 3 and those with bilateral 
unreactive pupils have a very poor prognosis regardless of 
treatment, their inclusion in the trial might bias any 
treatment effect towards the null. We therefore prespecified 
a sensitivity analysis that excluded these patients.11 Cause 
of death was assessed by the responsible clinician. 
Secondary outcomes were early head injury­related death 
(within 24 h after injury), all­cause and cause­specific 
mortality, disability, vascular occlusive events (myocardial 
infarction, stroke, deep vein thrombosis, and pulmonary 
embolism), seizures, complications, neuro­ surgery, days 
in intensive care unit, and adverse events within 28 days of 
randomisation. A diagnosis of deep vein thrombosis or 
pulmonary embolism was recorded only if a positive result 
was found on imaging (eg, ultrasound) or at a post­mortem 
examination.
We originally estimated that a trial with approximately 
10 000 patients would have 90% power (two­sided α=1%) 
to detect a 15% relative reduction (20–17%) in mortality.15 
However, we changed the primary outcome to head 
injury­related death in hospital within 28 days of injury 
in patients randomly assigned within 3 h of injury and 
limited recruitment to within 3 h of injury. We then 
increased the sample size to 13 000 to have approximately 
10 000 patients treated within 3 h of injury.11
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Statistical analysis
We published a statistical analysis plan before un­ 
blinding.11 The plan gave our reasons for limiting 
recruitment to within 3 h of injury and stated that 
outcomes for patients treated after 3 h of injury would be 
presented separately. All analyses were on an intention­
to­treat basis. For each binary outcome, we calculated 
RRs and 95% CIs. We did a complete case analysis with 
no imputation for missing data. The safety of participants 
was overseen by an independent data monitoring 
committee, which reviewed four unblinded interim 
analyses.
We planned to report the effects of tranexamic acid on 
the primary outcome stratified by three baseline 
characteristics: severity of head injury, time to treatment, 
and age. Severity of head injury was assessed using the 
baseline GCS score—mild to moderate (GCS 9–15) and 
severe (GCS 3–8)—and by pupil reactivity. We also 
assessed the effect of severity in a regression analysis 
that included continuous terms for GCS and its square. 
We expected that any beneficial effect of tranexamic acid 
would vary by time to treatment with earlier treatment 
being most effective. We examined this hypothesis in 
a subgroup analysis of the effect of tranexamic acid 
according to the estimated time interval between injury 
and treatment (≤1, >1 to ≤3, >3 h). We prespecified that 
this analysis would include patients treated within and 
beyond 3 h of injury. Because TBI severity, systolic blood 
pressure, and age could confound the effect of time to 
treatment on treatment effectiveness, we planned to 
control for these variables in a multivariable model. 
Because fibrinolytic activation after TBI might increase 
with age, we examined the effect of tranexamic acid on 
head injury­related death stratified by age: 30 years or 
younger, 31–60 years, older than 60 years. For subgroup 
analyses, we report p values for the test for heterogeneity.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding authors had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between July 20, 2012, and Jan 31, 2019, we recruited 
patients with TBI from 175 hospitals in 29 countries. 
We stopped recruiting when the trial treatment expired. 
We randomly allocated 12 737 patients to receive tranexamic 
acid (6406 [50·3%]) or matching placebo (6331 [49·7%]), of 
whom 12 561 (98·6%) received the first dose of the allocated 
treatment (figure 1). We enrolled 9202 (72·2%) patients 
within 3 h of injury. 40 patients withdrew consent after 
randomisation but 13 of these agreed to outcome data 
collection or had outcome data collected as part of adverse 
event reporting. We did not obtain primary outcome data 
for 75 (0·8%) patients. There were 98 (0·8%) protocol 
violations. 66 (0·5%) patients did not meet the inclusion 
criteria (32 had GCS scores >12 and no bleeding on 
CT scan, 11 had major extracranial bleeding, eight had a 
time since injury >8 h, six were younger than 16 years, 
three had non­traumatic bleeding, five had a combination 
of the above reasons, and one patient received tranexamic 
acid before randomisation). 32 (0·3%) patients were 
recruited during a lapse in the annual renewal of ethics 
committee approval in the UAE. These patients were 
recruited according to the approved procedure and 
approval was reissued after the lapse. 13 patients were 
unmasked to treatment. Baseline characteristics were 
similar between treatment groups for patients treated 
within 3 h of injury (table 1) and for those treated after 3 h 
(appendix 8 p 1). Figure 2 shows the number of deaths due 
to head injury and all other causes by days since injury in 
all patients. 2560 deaths occurred and the median time to 
death was 59 h after injury (IQR 20–151).
Table 2 shows the effect of tranexamic acid on head 
injury­related death in the 9127 patients randomly 
assigned within 3 h of injury with outcome data. Among 
these patients, the risk of head injury­related death was 
18·5% in the tranexamic acid group versus 19·8% in the 
placebo group (855 vs 892 events, RR 0·94 [95% CI 
0·86–1·02]). In the prespecified sensitivity analysis that 
excluded patients with a GCS score of 3 or bilateral 
unreactive pupils at baseline, the results were 12·5% in 
the tranexamic acid group versus 14·0% in the placebo 
group (485 vs 525 events, 0·89 [0·80–1·00]).
See Online for appendix 8
Figure 1: Trial profile
6406 allocated to tranexamic acid group 
4649 randomly assigned within 3h
6406 baseline data collected
4649 randomly assigned within 3h
16 withdrew consent
13 randomly assigned within 3h
9 outcome data unavailable
7 randomly assigned within 3h
38 lost to follow-up
29 randomly assigned within 3h
6314 received loading dose 
4576 randomly assigned within 3h
5984 received maintenance dose 
4308 randomly assigned within 3h
6359 patients with outcome data 
4613 randomly assigned within 3h
6331 allocated to placebo group
4553 randomly assigned within 3 h
12 737 patients randomly assigned
6331 baseline data collected 
4553 randomly assigned within 3h 
24 withdrew consent
19 randomly assigned within 3h
18 outcome data unavailable
14 randomly assigned within 3h
33 lost to follow-up
25 randomly assigned within 3h
6247 received loading dose
4488 randomly assigned within 3h
5882 received maintenance dose
4191 randomly assigned within 3h
6280 patients with outcome data
4514 randomly assigned within 3h
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We examined the effect of tranexamic acid on head 
injury­related death stratified by baseline GCS and 
pupillary reactions (figure 3). We found a reduction in 
the risk of head injury­related death with tranexamic 
acid in patients with mild­to­moderate head injury 
(RR 0·78 [95% CI 0·64–0·95]) but in patients with severe 
head injury (0·99 [0·91–1·07]) we found no clear evidence 
of a reduction (p value for heterogeneity 0·030). When 
we examined the effect of baseline GCS in a regression 
analysis we found evidence that tranexamic acid is more 
effective in less severely injured patients (p=0·007). 
Among patients with reactive pupils, head injury­related 
deaths were reduced with tranexamic acid (0·87, 
[0·77–0·98]).
We examined the effect of tranexamic acid on head 
injury­related death stratified by time to treatment and 
recorded no evidence of heterogeneity (p=0·96). The 
RR of head injury­related death with tranexamic acid was 
0·96 (95% CI 0·79–1·17) in patients randomly assigned 
within 1 h of injury, 0·93 (0·85–1·02) in those randomly 
assigned within more than 1 h and 3 h or fewer after 
injury, and 0·94 (0·81–1·09) in those randomly assigned 
more than 3 h after injury. However, as anticipated in the 
statistical analysis plan, patients who are treated soon 
after injury often have more severe head injury and so 
the effect of time to treatment could be confounded by 
severity. Figure 4 shows effect of time to treatment on the 
effect of tranexamic acid in patients with a mild and 
moderate head injury and in those with severe head injury 
after adjusting for GCS, systolic blood pressure, and age 
in a multivariable model including all participants. Early 
treatment was more effective than later treatment in 
patients with mild and moderate head injury (p=0·005) 
but we found no obvious effect of time to treatment 
Tranexamic 
acid (n=4649)
Placebo 
(n=4553)
Sex*
Men 3742 (80%) 3660 (80)
Women 906 (19%) 893 (20)
Age, years
Mean (SD) 41·7 (19·0) 41·9 (19·0)
<25 1042 (22%) 996 (22%)
25–44 1716 (37%) 1672 (37%)
45–64 1169 (25%) 1184 (26%)
≥65 722 (16%) 701 (15%)
Time since injury, h
Mean (SD) 1·9 (0·7) 1·9 (0·7)
≤1 877 (19%) 869 (19%)
>1–2 2003 (43%) 1889 (41%)
>2–3 1769 (38%) 1795 (39%)
Systolic blood pressure, mm Hg
<90 89 (2%) 85 (2%)
90–119 1508 (32%) 1490 (33%)
120–139 1461 (31%) 1504 (33%)
≥140 1576 (34%) 1466 (32%)
Unknown 15 (<1%) 8 (<1%)
Glasgow Coma Scale score
3 495 (11%) 506 (11%)
4 213 (5%) 213 (5%)
5 163 (4%) 172 (4%)
6 221 (5%) 232 (5%)
7 311 (7%) 294 (6%)
8 354 (8%) 315 (7%)
9 335 (7%) 292 (6%)
10 371 (8%) 364 (8%)
11 375 (8%) 390 (9%)
12 476 (10%) 478 (10%)
13 297 (6%) 312 (7%)
14 526 (11%) 458 (10%)
15 484 (10%) 492 (11%)
Unknown 28 (1%) 35 (1%)
Pupil reaction
None reacted 425 (9%) 440 (10%)
One reacted 374 (8%) 353 (8%)
Both reacted 3706 (80%) 3636 (80%)
Unable to assess or unknown 144 (3%) 124 (3%)
Data are n (%), unless otherwise indicated. *In the tranexamic acid group, 
one patient’s sex was unknown.
Table 1: Baseline characteristics of patients before randomisation of 
those randomly assigned within 3 h of injury
Figure 2: Mortality by days since injury among all patients
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
0
100
200
300
400
500
600
700
800
De
at
hs
 (n
)
Days since injury
Deaths due to head injury
Deaths due to all other causes
Tranexamic acid Placebo Risk ratio (95% CI)
All 855/4613 (18·5%) 892/4514 (19·8%) 0·94 (0·86–1·02)
Excluding patients with GCS score of 3 or 
bilateral unreactive pupils*
485/3880 (12·5%) 525/3757 (14·0%) 0·89 (0·80–1·00)
GCS=Glasgow Coma Scale. *Prespecified sensitivity analysis.
Table 2: Effect of tranexamic acid on head injury-related death in patients randomly assigned within 3 h 
of injury
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in patients with severe head injury (p=0·73). The 
effectiveness of tranexamic acid by time to treatment 
stratified by severity is further shown in the appendix 8 
(p 3). We found no evidence of heterogeneity in the effect 
of tranexamic acid by patient age (p=0·45).
We examined the effect of tranexamic acid on head 
injury­related death stratified by World Bank income 
group (high­income vs low­income and middle­income 
countries). This analysis was not prespecified. Although 
the reduction in the risk of head injury­related death 
with tranexamic acid was larger in high­income 
countries (RR 0·76 [95% CI 0·55–1·04]) than in low­
income and middle­income countries (0·92 [0·81–1·04]), 
we found no statistical evidence of heterogeneity by 
country income group (p=0·26).
Because early head injury­related deaths are more 
likely to result from intracranial haemorrhage than are 
late head injury­related deaths, we examined the effect 
of tranexamic acid on head injury­related death within 
24 h of injury. The RR of head injury­related death was 
0·81 (95% CI 0·69–0·95) within 24 h. When patients 
with a GCS score of 3 and those with bilateral unreactive 
pupils at baseline were excluded, the RR was 0·72 
(0·56–0·92) within 24 h.
The RR for non­head injury­related deaths was 
1·31 (95% CI 0·93–1·85) and 0·96 (0·89–1·04) for all­
cause mortality. The results for non­head injury­related 
deaths broken down by cause are presented in the 
appendix 8 (p 2).
We assessed the effect of tranexamic acid on disability 
in survivors by comparing the mean Disability Rating 
Scale score (lower score means less disabled) between 
the tranexamic acid and placebo groups. The mean 
scores were similar between groups for patients treated 
within 3 h of injury (4·99 [SD 7·6] in the tranexamic acid 
group vs 5·03 [7·6] in the placebo group) and for those 
treated after 3 h (4·52 [7·0] in the tranexamic acid group 
vs 5·00 [7·4] in the placebo group). We also examined the 
effect of tranexamic acid on disability (table 3) using an 
outcome measure designed by patient representatives by 
estimating the RR of being in the most extreme category 
for six areas of functioning (walking, washing, pain and 
discomfort, anxiety or depression, agitation or aggres­
sion, and fatigue). The prevalence of disability among 
survivors was similar between groups.
The risk of vascular occlusive events and other 
complications was similar in the tranexamic acid and 
placebo groups (table 3). We found no evidence that 
tranexamic acid increased fatal or non­fatal stroke 
(RR 1·08 [95% CI 0·71–1·64]). The risk of seizures was 
similar between groups (1·09 [95% CI 0·90–1·33]). The 
numbers of other adverse events were similar between 
groups (appendix 8 p 4).
Discussion
This trial provides evidence that the administration 
of tranexamic acid to patients with TBI within 3 h 
of injury reduces head injury­related death, with no 
evidence of adverse effects or complications. We found 
a substantial reduction in head injury­related deaths 
with tranexamic acid in patients with mild and 
moderate head injuries but no apparent reduction in 
those with severe head injury. We found no increase in 
disability among survivors.
Our trial had several strengths but also some 
limitations. The method of randomisation ensured that 
partici pating clinicians had no foreknowledge of the 
treatment allo cation and the use of placebo control 
ensured that outcome assessments were blind to the 
intervention. Although the eligibility criteria required 
the recruiting clinician to be uncertain as to the 
appropriateness of tranexamic acid treatment, because 
tranexamic acid is not a recommended treatment for 
patients with isolated TBI, almost all patients with TBI 
who met the inclusion criteria were recruited. Baseline 
Figure 3: Effect of tranexamic acid on head injury-related death stratified by baseline severity in patients 
randomised within 3 h of injury
RR=risk ratio. GCS=Glasgow Coma Scale.
Figure 4: Effect of tranexamic acid on head injury-related death by severity and time to treatment in all patients
The models were adjusted for GCS score, age, and systolic blood pressure. 537 patients with mild and moderate 
GCS scores (9–15) and 918 patients with severe GCS scores (4–8), excluding those with a GCS score of 3 and those 
with no reactive pupils, died because of head injury. GCS=Glasgow Coma Scale.
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prognostic factors were well balanced and because 
almost all randomly assigned patients were followed up 
there was little potential for bias. The analysis was by 
intention to treat. The primary outcome was head 
injury­related death as assessed by the responsible 
clinician. Although some misclassification of cause of 
death is inevitable, the assessment was made blind to 
the trial treatment. All­cause mortality combines causes 
of death that might be affected by tranexamic 
acid (eg, head injury­related death due to intracranial 
bleeding) with causes that we do not expect to be 
affected by tranexamic acid (eg, sepsis) and therefore 
would be biased towards the null. Although the 
CRASH­3 trial is one of the largest trials in patients 
with TBI, the CIs were wide and compatible with a 
substantial reduction in head injury­related death and 
little or no benefit. On the other hand, when set in the 
context of all the available randomised trials of 
tranexamic acid in patients with TBI (figure 5), the 
possibility of no mortality benefit appears remote 
(NCT01990768).9,10 When assessing outcome measures 
in clinical trials, provided there are few false positives 
(high specificity), estimates of the RR are unbiased even 
when sensitivity is imperfect.16 For this reason, a 
diagnosis of deep vein thrombosis or pulmo nary 
embolism was recorded only if we found a positive 
result on imaging (eg, ultrasound) or at post­mortem 
examination. As a result, although the trial might have 
<3 h ≥3 h All
Tranexamic 
acid (n=4613)
Placebo 
(n=4514)
RR 
(95% CI)
Tranexamic 
acid (n=1746)
Placebo 
(n=1766)
RR 
(95% CI)
Tranexamic 
acid (n=6359)
Placebo 
(n=6280)
RR 
(95% CI)
Patient-derived disability measures*
Confined to bed 579 (12·6%) 549 (12·2%) 1·03 (0·93–1·15) 190 (10·9%) 222 (12·6%) 0·87 (0·72–1·04) 769 (12·1%) 771 (12·3%) 0·99 (0·90–1·08)
Unable to wash or dress 580 (12·6%) 583 (12·9%) 0·97 (0·87–1·08) 195 (11·2%) 228 (12·9%) 0·87 (0·72–1·04) 775 (12·2%) 811 (12·9%) 0·94 (0·86–1·03)
Severe pain or discomfort 38 (0·8%) 29 (0·6%) 1·28 (0·79–2·08) 10 (0·6%) 10 (0·6%) 1·01 (0·42–2·42) 48 (0·8%) 39 (0·6%) 1·22 (0·80–1·85)
Severe anxiety or depression 43 (0·9%) 41 (0·9%) 1·03 (0·67–1·57) 19 (1·1%) 20 (1·1%) 0·96 (0·51–1·79) 62 (1·0%) 61 (1·0%) 1·00 (0·71–1·43)
Severe agitation or aggression 53 (1·1%) 53 (1·2%) 0·98 (0·67–1·43) 14 (0·8%) 27 (1·5%) 0·52 (0·28–1·00) 67 (1·1%) 80 (1·3%) 0·83 (0·60–1·14)
Severe fatigue 100 (2·2%) 101 (2·2%) 0·97 (0·74–1·27) 40 (2·3%) 43 (2·4%) 0·94 (0·61–1·44) 140 (2·2%) 144 (2·3%) 0·96 (0·76–1·21)
Complications†
All vascular occlusive events 69 (1·5%) 60 (1·3%) 1·13 (0·80–1·59) 32 (1·8%) 42 (2·4%) 0·77 (0·49–1·21) 101 (1·6%) 102 (1·6%) 0·98 (0·74–1·28)
Pulmonary embolism 18 (0·4%) 18 (0·4%) 0·98 (0·51–1·88) 6 (0·3%) 14 (0·8%) 0·43 (0·17–1·13) 24 (0·4%) 32 (0·5%) 0·74 (0·44–1·26)
Deep vein thrombosis 15 (0·3%) 12 (0·3%) 1·22 (0·57–2·61) 4 (0·2%) 4 (0·2%) 1·01 (0·25–4·04) 19 (0·3%) 16 (0·3%) 1·17 (0·60–2·28)
Stroke 29 (0·6%) 23 (0·5%) 1·23 (0·71–2·13) 17 (1·0%) 19 (1·1%) 0·90 (0·47–1·74) 46 (0·7%) 42 (0·7%) 1·08 (0·71–1·64)
Myocardial infarction 9 (0·2%) 12 (0·3%) 0·73 (0·31–1·74) 9 (0·5%) 8 (0·5%) 1·14 (0·44–2·94) 18 (0·3%) 20 (0·3%) 0·89 (0·47–1·68)
Renal failure 73 (1·6%) 56 (1·2%) 1·28 (0·90–1·80) 27 (1·5%) 28 (1·6%) 0·98 (0·58–1·65) 100 (1·6%) 84 (1·3%) 1·18 (0·88–1·57)
Sepsis 297 (6·4%) 279 (6·2%) 1·04 (0·89–1·22) 114 (6·5%) 133 (7·5%) 0·87 (0·68–1·10) 411 (6·5%) 412 (6·6%) 0·99 (0·86–1·12)
Seizure 130 (2·8%) 105 (2·3%) 1·21 (0·94–1·56) 76 (4·4%) 81 (4·6%) 0·95 (0·70–1·29) 206 (3·2%) 186 (3·0%) 1·09 (0·90–1·33)
Gastrointestinal bleeding 16 (0·3%) 22 (0·5%) 0·71 (0·37–1·35) 8 (0·5%) 13 (0·7%) 0·62 (0·26–1·50) 24 (0·4%) 35 (0·6%) 0·68 (0·40–1·14)
RR=risk ratio. *Includes survivors only. †Includes fatal and non-fatal events.
Table 3: Effect of tranexamic acid on disability, vascular occlusive events, and other complications in patients randomly assigned within 3 h, patients randomised beyond 3 h, and all patients
Figure 5: Evidence on the effect of tranexamic acid on head injury-related death
RR=risk ratio.
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underestimated the risk of deep vein thrombosis or 
pulmonary embolism, the RR estimates for this 
outcome should be unbiased.
We anticipated that patients with TBI with a GCS 
score of 3 and those with bilateral unreactive pupils 
before treatment would have little potential to benefit 
from tranexamic acid and that their inclusion in the 
analysis would bias the treatment effect towards the 
null. Most patients with bilateral unreactive pupils 
already have extensive intracranial haemorrhage and 
brain herniation and so tranexamic acid is unlikely to 
improve the out come in these patients. We therefore 
prespecified a sensitivity analysis that excluded these 
patients. However, patients with unilateral unreactive 
pupils were not excluded and because many of these 
patients have brain herniation their inclusion might 
also have diluted the treatment effect. Indeed, when 
patients with a GCS score of 3 and those with unilateral 
or bilateral unreactive pupils before treatment were 
excluded in a post­hoc analysis, the treatment effect was 
noticeably larger.
The effect of tranexamic acid on head injury­related 
death appears to depend on the time interval between 
injury and the initiation of the trial treatment and on the 
severity of TBI. Early treatment of patients with mild 
(GCS 13–15 and intracranial bleeding on baseline CT 
scan) and moderate head injury seemed to confer the 
greatest mortality benefit. This finding is consistent with 
the hypothesis that tranexamic acid improves outcome 
by reducing intracranial bleeding. Because haemorrhage 
expansion occurs in the hours immediately after injury, 
treatment delay would reduce the potential for tranexamic 
acid to prevent intracranial bleeding.3,4 Patients with 
severe head injury might have less to gain from 
tranexamic acid treatment than patients with mild­to­
moderate head injury because such patients already have 
extensive intracranial haemorrhage before treatment or 
other potentially life­threatening intracranial pathologies 
that are not affected by tranexamic acid. We anticipated 
in our statistical analysis plan that the effect of tranexamic 
acid would be greater for head injury­related deaths 
occurring in the first few days after injury than for late 
head injury­related deaths because early head injury­
related deaths are more likely due to bleeding. Our data 
supports this hypothesis, showing a substantial reduction 
in head injury­related deaths within 24 h of injury. 
Similar results were obtained in the CRASH­2 trial of 
tranexamic acid in patients with traumatic extracranial 
bleeding, in which the effect of tranexamic acid on death 
from bleeding was greatest on the day of the injury 
(RR 0·72 [95% CI 0·60–0·86]).17 However, thereafter the 
benefit of tranexamic acid in head injury patients was 
slightly attenuated, probably because patients succumbed 
to non­bleeding­related pathophysiological mechanisms. 
This finding might explain why the effect of early 
tranexamic acid treatment on head injury­related death is 
slightly smaller than the effect of tranexamic acid on 
death due to bleeding seen in the CRASH­2 trial.
We found no evidence of any increased risk of adverse 
events. In particular, the risk of deep vein thrombosis, 
pulmonary embolism, stroke, and myocardial infarction 
was similar in the tranexamic acid and placebo groups. 
This finding is consistent with the results of the 
CRASH­2 trial, which also found no increased risk of 
vascular occlusive events with tranexamic acid. Unlike 
in the CRASH­2 trial, we found no evidence that 
administration beyond 3 h of injury increased the risk of 
head injury­related death or any other adverse events. 
Indeed, given the absence of any adverse effects in this 
trial, the implications of wrongly concluding that 
tranexamic acid is ineffective are likely to be far more 
consequential than are those of wrongly concluding that 
tranexamic acid is effective.
On the basis of the CRASH­2 trial results, tranexamic 
acid was included in guidelines for the pre­hospital care of 
patients with trauma. However, patients with isolated TBI 
were specifically excluded. The CRASH­3 trial provides 
evidence that tranexamic acid is safe in patients with TBI 
and that treatment within 3 h of injury reduces head 
injury­related deaths.
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Nur Shahidah Binti Dzulkiflee, Wong Chok Ky, and 
Muhaimin Azwan Bin Mohd Azman; Hospital Raja Permaisuri Bainun 
(101): Adi Bin Osman, Azma Haryaty Ahmad, Ramzuzaman Ismail, 
and Si Qi Lai; Hospital Sultanah Aminah (94): Mohd Amin Bin Mohidin, 
Norwani Binti Deraman, and Salliza Binti Selamat; Hospital Tuanku 
Fauziah (72): Ida Abidin, Nurkhairulnizam Halim, and Zuraini Bakar; 
Hospital Tengku Ampuan Afzan (41): Zainalabidin Mohamed Ismail, 
Badrul Hisham, and Ruhaida Kamal; Hospital Sultan Abdul Halim (36): 
Zainal Effendy and Mashitah Ismail; Hospital Seberang Jaya (30): 
Noor Azleen and Liu Yeo Seng; Universiti Sains Malaysia (26): 
Kamarul Aryffin Baharuddin and Regunath Kandasamy; Hospital 
Langkawi (13): Azlan Kamalludin; Hospital Kulim (8): Shamsul Asmee; 
Hospital Kemaman (7): Mohd Fadzil; Hospital Segamat (6): 
Ahmad Basitz; Hospital Pakar Sultanah Fatimah (5): Norhaya Abdullah. 
Georgia (771)— High Technology Medical Center, University Clinic (751): 
Tamar Gogichaishvili, Giorgi Ingorokva, Shota Ingorokva, 
Iamze Agdgomelashvili, Kote Mumladze, Ioseb Maisuradze, and 
Iulia Kugusheva; Archangel St Michael Multiprofile Clinical Hospital 
(18): Buba Shalamberidze; City Hospital 1 (2): Gia Tomadze. 
Spain (425)—Hospital Regional Universitario Carlos Haya (102): 
Juan Fernandez­Ortega, Raimundo Seara­Valero, 
Guillermo Ibañez­Botella, Victoria Garcia­Martinez; Hospital Alvaro 
Cunqueiro VIGO (82): Melida Garcia Martul, Santiago Freita Ramos, 
Guillermo Lago Preciado; Hospital Universitario Virgen del Rocio (77): 
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Claudio Garcia­Alfaro, Angeles Munoz­Sanchez, Rafael Bellido­Alba; 
Hospital General Universitario de Ciudad Real (67): Carmen Corcobado, 
Ana Bueno, Alfonso Ambros; Complejo Hospitalario de Navarra (44): 
JuanTihista Jimenez, Jose Roldan Ramirez; Hospital Torrecardenas (21): 
José Martín; Hospital de Lucus Augusti (13): Laura Inés Rodríguez; 
Hospital Clinico de Barcelona (9): Jaime Fontanals; Hospital 
Universitario Puerta del Mar de Cadiz (9): José Manuel Jiménez­Moragas; 
Hospital General Universitario De Albacete (1): Joaquín Paya Berbegal. 
Nigeria (409)—National Hospital Abuja (64): Olaomi Oluwole, 
Raji Mahmud, and Nancy Ukwu; Lagos University Teaching Hospital 
(55): Femi Bankole, Abidemi Oseni, and Bamidele Adebayo; University 
College Hospital, Ibadan (53): Adefolarin Malomo, Liadi Tiamiyu, and 
Adefisayo Adekanmbi; Olabisi Onabanjo University Teaching Hospital 
(38): Lateef Thanni and Ayodeji Olubodun; Federal Medical Centre 
Abeokuta (36): Fidelis Ojeblenu and Michael Uwaezuoke; Obafemi 
Awolowo University Teaching Hospitals (31): Edward Komolafe and 
Oluwafemi Owagbemi; Lagos State Accident and Emergency Centre 
(22): Fatai Ishola; Bowen University Teaching Hospital Ogbomoso (17): 
Adewumi Durodola; Federal Medical Centre Lokoja (13): Ukpong Udoffa, 
Federal Medical Centre Bida (12): Adeniran James; Abubakar Tafawa 
Balewa University Teaching Hospital (11): Azeez Tella; Irrua Specialist 
Teaching Hospital (9): Andrew Dongo; Federal Medical Centre Umuahia 
(8): Uchechi Ekpemiro; Nnamdi Azikiwe University Teaching Hospital 
(8): Stanley Anyanwu; State Hospital, Ijaiye, Abeokuta (8): Nafiu Aigoro; 
University of Nigeria Teaching Hospital Enugu (7): Wilfred Mezue; 
Jos University Teaching Hospital (6): Danaan Shilong; University of 
Benin Teaching Hospital (6): Abiodun Azeez; Federal Medical Centre 
Ido­Ekiti (2): Olakunle Babalola; Federal Teaching Hospital, Gombe (2): 
Mohammed Ibrahim; University of Abuja Teaching Hospital (1): 
Joseph Obande. Colombia (335)—Hospital Pablo Tobon Uribe (127), 
Alfredo Constain Franco, Edwin Vasquez Salazar, Sebastian Betancur 
Londoño, and Viviana Medina Cardona; Hospital Universitario 
San Vicente Fundacion (112): Carlos Morales; Santiago Upegui; 
Santiago Naranjo; July Agudelo; Fundacion Valle del Lili (96): 
Jorge Mejia­Mantilla, Sandra Carvajal, and Yidhira Fajardo­Gaviria. 
Nepal (255)—Neuro Hospital (103): Yam Roka, Ushma Ghising, 
Narayani Roka, and Manzil Shrestha; National Institute of Neurological 
and Allied Sciences (64): Upendra Devkota, Bivek Vaidya, and 
Pankaj Nepal; Kathmandu Medical College Teaching Hospital (47): 
Amit Thapa and Bidur KC; Chitwan Medical College Teaching Hospital 
(24): Ajit Shrestha; Bir Hospital (11): Rajiv Jha; B & B Hospital Ltd. 
(6): Prabin Shrestha. Albania (214)—University Hospital of Trauma 
(214): Fatos Olldashi, Irgen Hodaj, Erion Spaho, Asllan Selaj, 
and Nirian Bendo. Japan (165)—Matsudo City Hospital (64): 
Tomohisa Shoko, Hideki Endo, and Atsushi Senda; Senshu Trauma 
and Critical Care Centre (61): Yasushi Hagihara, Takashi Fuse, and 
Naohisa Masunaga; Tokyo Medical and Dental University (28): 
Yasuhiro Otomo and Ryuichiro Egashira; Teikyo University Hospital 
(12): Takahiro Ohnuki. United Arab Emirates (126)—Al Qassimi Hospital 
(126): Satish Krishnan, Alya AlMazmi, Subrata Saha, and 
Alexander Suvarov. Myanmar (121)—1000 Bedded Nay Pyi Taw Hospital 
(121): Than Latt Aung, Kaung Myat Tun, Tint Tint Khaing, and 
Thinzar Maw. Cameroon (116)—Yaounde Central Hospital (38): 
Vincent Djientcheu and Orlane Ndome; Hopital General Douala (31): 
Mireille Moumi and André Mbida; Hopital Laquintinie de Douala (28): 
Joseph Fondop and N’Diaye; Yaounde General Hospital (19): 
Mba Sebastien. Afghanistan (87)—Nangarhar University Teaching 
Hospital (87): Abdul Azim, Jan Adil, and Zabiullah Amiry. Mexico (79)—
Hospital Regional 25 IMSS (24): Jorge Loría­Castellanos; Hospital 
General Jose G Parres (21): Nancy Guevara Rubio; Hospital General de 
Uruapan, Pedro Daniel Martinez (11): Patricia Ortega Leon; Hospital 
General Regional No 1 (10): Francisco Estrada; Hospital General de Zona 
197 (8): Erandy Montes de Oca­García; Hospital General Regional 
Bernardo Sepulveda (3): Hafid Sanchez; Hospital General La Perla (2): 
Angélica Soria. Italy (72)—Azienda Ospedaliera Universitaria Senese 
(35): Paola Bonucci and Federico Franchi; Fondazione Poliambulanza 
(19): Alan Girardini; Spedali Civili Di Brescia (18): Frank Rasulo. 
Iraq (55)—Rozhawa Emergency Hospital (51): Qadamkhear Hama, 
Himdad Hameed, and Muhammad Basim; Rojhelat Emergency Hospital 
(3): Qadamkhear Hama; Par Hospital (1): Qadamkhear Hama. 
Cambodia (45)—World Mate Emergency Hospital (45): Simon Stock and 
Eap Hourt. Zambia (44)—University Teaching Hospital Lusaka (40): 
Yakub Mulla and Ali Ilunga; Kitwe Central Hospital (4): 
Jonathan Mulenga. Romania (35)—Timisoara County Hospital (17): 
Horia Ples; Spitalul Sf Pantelimon Bucharest (11): Adam Danil; 
Bagdasar­Arseni Emergency Clinical Hospital (5): Mircea Gorgan; 
Cluj County Emergency Hospital (2): Ioan Florian. El Salvador (28)—
Hospital Nacional Rosales (28): Juan Tobar, Fernandez. 
Egypt (20)—Mataria Teaching Hospital (20): Hussein Khamis. 
Slovenia (15)—University Medical Centre Ljubljana (15): Dusan Vlahovic. 
Ireland (12)—Cork University Hospital (12): Conor Deasy. 
Papua New Guinea (10)—Port Moresby General Hospital (10): 
Bobby Wellsh. Canada (7)—Saint John Regional Hospital (7): 
James French. Jamaica (7)—Cornwall Regional Hospital (5): Jeffrey East; 
University Hospital of the West Indies (2): Jean Williams­Johnson. 
Indonesia (6)—Rumah Sakit Sekar Kamulyan (6): Antonius Kurniawan. 
Kenya (1)—Kenyatta National Hospital, University of Nairobi (1): 
Julius Kiboi.
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